Synonyms: BN-201 | BN201 | OCS-05
Compound class:
Synthetic organic
Comment: The chemical structure for privosegtor was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a serum/ glucocorticoid-regulated kinase 2 (SGK2) activator. This is a structural match for clinical candidate OCS-05 (also known as BN201) that is being investigated as a neuroprotective therapy [2].
|
|
No information available. |
Summary of Clinical Use ![]() |
As OCS-05 this SGK2 peptidomimetic has advanced to clinical evaluation for efficacy in acute optic neuritis and multiple sclerosis [1]. OCS-05 is administered intravenously. As SN201 this agent was was granted FDA orphan designation for the treatment of optic neuritis in 2014. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04762017 | OCS-05 in Patients With Acute Optic Neuritis | Phase 2 Interventional | Oculis | ||
NCT03630497 | BN201 SAD MAD Study in Healthy Subjects | Phase 1 Interventional | Accure Therapeutics |